- Home
- DOUG vs DMAC Comparison
DOUG vs DMAC Comparison
Compare DOUG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- DMAC
- Stock Information
- Founded
- DOUG 1911
- DMAC 2000
- Country
- DOUG United States
- DMAC United States
- Employees
- DOUG N/A
- DMAC N/A
- Industry
- DOUG Building operators
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- DMAC Health Care
- Exchange
- DOUG Nasdaq
- DMAC Nasdaq
- Market Cap
- DOUG 161.5M
- DMAC 178.0M
- IPO Year
- DOUG N/A
- DMAC N/A
- Fundamental
- Price
- DOUG $2.31
- DMAC $3.76
- Analyst Decision
- DOUG
- DMAC Strong Buy
- Analyst Count
- DOUG 0
- DMAC 2
- Target Price
- DOUG N/A
- DMAC $8.00
- AVG Volume (30 Days)
- DOUG 1.0M
- DMAC 307.4K
- Earning Date
- DOUG 08-06-2025
- DMAC 08-06-2025
- Dividend Yield
- DOUG N/A
- DMAC N/A
- EPS Growth
- DOUG N/A
- DMAC N/A
- EPS
- DOUG N/A
- DMAC N/A
- Revenue
- DOUG $1,048,791,000.00
- DMAC N/A
- Revenue This Year
- DOUG $17.61
- DMAC N/A
- Revenue Next Year
- DOUG N/A
- DMAC N/A
- P/E Ratio
- DOUG N/A
- DMAC N/A
- Revenue Growth
- DOUG 11.36
- DMAC N/A
- 52 Week Low
- DOUG $1.03
- DMAC $2.80
- 52 Week High
- DOUG $3.20
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- DOUG 45.13
- DMAC 47.18
- Support Level
- DOUG $2.27
- DMAC $3.48
- Resistance Level
- DOUG $2.46
- DMAC $3.99
- Average True Range (ATR)
- DOUG 0.13
- DMAC 0.32
- MACD
- DOUG -0.06
- DMAC -0.00
- Stochastic Oscillator
- DOUG 15.80
- DMAC 41.01
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.